MAX Chat
WuXi Biologics (Cayman) Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
7/10
|
20.91 | 194.06 | -89.22% | 56.47 | -62.97% |
| P/S |
|
3.76 | 137.31 | -97.26% |
|
|
| P/BV |
|
1.54 | 18.94 | -91.85% |
|
|
| P/FCF |
|
12.57 | 32.98 | -61.89% |
|
|
| Ev/Ebitda |
|
10.4 | 18.42 | -43.56% |
|
|
| Ev/S |
|
3.58 | 5.07 | -29.42% |
|
|
| Ev/FCF |
|
51.92 | 56.5 | -8.11% |
|
|
| E/P |
|
0.2074 | 4.21 | -95.08% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
9/10
|
34.43 | -48.93 | -170.35% | 33.91 | +1.52% |
| ROE |
|
8.17 | 42.1 | -80.59% |
|
|
| ROA |
|
5.91 | 20.11 | -70.61% |
|
|
| ROIC |
|
11.15 | 13.46 | -17.15% |
|
|
| ROS |
|
17.97 | -68.41 | -126.27% |
|
|
| ROCE |
|
10.98 | 157.85 | -93.04% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
9/10
|
0.7684 | 0.9881 | -22.24% | 0.8059 | -4.65% |
| Nеt Debt/Ebitda |
|
-0.5194 | 0.0409 | -1368.53% |
|
|
| Debt/Ratio |
|
0.0867 | 0.1623 | -46.58% |
|
|
| Debt/Equity |
|
0.2529 | 1.58 | -83.98% |
|
|
| Debt/Net Income |
|
1.47 | 33.69 | -95.63% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.67 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.17 | -100% | ||
| DSI |
|
0 | 0.6961 | -100% |
|
|
| Average dividend growth |
|
0 | -487.91 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 27.53 | -100% |
|
|
| Average percentage for payments |
|
130.35 | 169.1 | -22.92% |
|
|
| Difference from average difference in sector |
|
-1.67 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
232.75 | 141.77 | 64.17% | ||
| Growth impulse Ebitda in 5 years |
|
262.97 | 116.51 | 125.71% | ||
| Growth impulse Net Income in 5 years |
|
98.72 | 22.03 | 348.12% | ||
| Growth impulse FCF in 5 years |
|
-131.08 | 16.27 | -905.65% | ||
| Growth impulse EPS in 5 years |
|
1916.83 | 49.02 | 3810.3% |
IP Score
5.96/10
